AXGT:NSD-Axovant Gene Therapies Ltd (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 4.09

Change

0.00 (0.00)%

Market Cap

USD 0.17B

Volume

3.22M

Average Target Price

USD 13.00 (+217.85%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Axovant Gene Therapies Ltd., a clinical-stage company, develops gene therapies for neurodegenerative diseases. The company's product pipeline includes AXO-Lenti-PD program, an in vivo lentiviral gene therapy for the treatment of Parkinson's disease, which is in Phase II clinical trials; the AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis is in Phase I/II clinical trials; and the AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis that is in Phase I/II clinical trials. It has a license agreement with Oxford BioMedica (UK) Ltd.; license and collaboration agreement with Benitec Biopharma Limited; exclusive license agreement with The University of Massachusetts Medical School; and collaboration agreement with Invitae Corporation. The company was formerly known as Axovant Sciences Ltd. The company was founded in 2014 and is based in London, the United Kingdom.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD72.87B 34.32 27.50
REGN Regeneron Pharmaceuticals, Inc

N/A

USD59.07B 21.90 16.92
SGEN Seattle Genetics, Inc

N/A

USD31.48B N/A N/A
MRNA Moderna, Inc

N/A

USD27.57B N/A N/A
RPRX Royalty Pharma plc

N/A

USD25.49B 35.14 9.58
GMAB Genmab A/S

N/A

USD25.19B 27.12 3.06
ALXN Alexion Pharmaceuticals, Inc

N/A

USD24.92B 30.43 27.52
BGNE BeiGene, Ltd

N/A

USD23.57B N/A N/A
IMMU Immunomedics, Inc

N/A

USD19.77B N/A N/A
INCY Incyte Corporation

N/A

USD18.98B 47.64 35.20

ETFs Containing AXGT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -20.12% 31% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.12% 31% F 34% F
Trailing 12 Months  
Capital Gain -47.36% 15% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -47.36% 15% F 11% F
Trailing 5 Years  
Capital Gain -96.46% 13% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -96.46% 13% F 4% F
Average Annual (5 Year Horizon)  
Capital Gain -19.80% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.80% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 28.57% N/A N/A N/A N/A
Risk Adjusted Return -69.28% N/A N/A N/A N/A
Market Capitalization 0.17B 37% F 38% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.61 70% C- 45% F
Price / Cash Flow Ratio -2.54 27% F 67% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -120.92% 24% F 10% F
Return on Invested Capital -78.49% 36% F 12% F
Return on Assets -37.29% 30% F 9% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.67 80% B- 80% B-
Short Percent 1.16% 90% A- 76% C
Beta 1.52 49% F 29% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.